Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO!

After months of negotiations, Takeda Canada announced it has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) with a Letter of Intent (LOI) regarding TAKHZYRO® (lanadelumab injection) for routine prevention of HAE attacks in adolescents and adults (12 years of age and older).

This means that Takeda Canada is now able to work towards implementing public funding for TAKHZYRO for eligible HAE patients.

Please click here to the learn the full details in Takeda’s press release.